China SXT Pharmaceuticals (SXTC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.1M

Revenue (quarter)

$1.1M

Revenue growth (year over year)

−34.63%

Gross profit (trailing twelve months)

$248,702.00

Gross margin

21.85%

Net income (trailing twelve months)

−$6.2M

Net income (quarter)

−$6.2M

Net income growth (year over year)

−87.83%

Net margin

−545.24%

Return on equity

−27.49%

EPS (trailing twelve months)

−$730.40

Book value per share

$2,480.59

P/E (trailing twelve months)

—

Price to book

0.02

Debt to assets

14.52%

Payout ratio

—

Dividend yield

—

Company profile

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

• Is China SXT Pharmaceuticals (SXTC) profitable?

  No. China SXT Pharmaceuticals reported a net loss of $6.2M over the trailing twelve months.

• How much revenue does China SXT Pharmaceuticals (SXTC) make?

  China SXT Pharmaceuticals generated $1.1M in revenue over the trailing twelve months, down 34.63% year over year.

• How do I buy stock in China SXT Pharmaceuticals (SXTC)?

  SXTC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.